Found: 96
Select item for more details and to access through your institution.
Plasma Ceramides and Other Sphingolipids in Relation to Incident Prediabetes in a Longitudinal Biracial Cohort.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2024, v. 109, n. 10, p. 2530, doi. 10.1210/clinem/dgae179
- By:
- Publication type:
- Article
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
- Published in:
- 2022
- By:
- Publication type:
- Letter
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5
- By:
- Publication type:
- Article
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687
- By:
- Publication type:
- Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
- By:
- Publication type:
- Article
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
- By:
- Publication type:
- Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
- By:
- Publication type:
- Article
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1245, doi. 10.1111/dom.14691
- By:
- Publication type:
- Article
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1114, doi. 10.1111/dom.14677
- By:
- Publication type:
- Article
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2276, doi. 10.1111/dom.14150
- By:
- Publication type:
- Article
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 3, p. 530, doi. 10.1111/dom.13116
- By:
- Publication type:
- Article
Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 409, doi. 10.1111/dom.13086
- By:
- Publication type:
- Article
Regression from prediabetes to normal glucose regulation: State of the science.
- Published in:
- Experimental Biology & Medicine, 2020, v. 245, n. 10, p. 889, doi. 10.1177/1535370220915644
- By:
- Publication type:
- Article
Plasma lipid levels predict dysglycemia in a biracial cohort of nondiabetic subjects: Potential mechanisms.
- Published in:
- Experimental Biology & Medicine, 2016, v. 241, n. 17, p. 1961, doi. 10.1177/1535370216659946
- By:
- Publication type:
- Article
Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications.
- Published in:
- Experimental Biology & Medicine, 2016, v. 241, n. 12, p. 1323, doi. 10.1177/1535370216654227
- By:
- Publication type:
- Article
Plasma Leptin and Insulin Relationships in Obese and N0nobese Humans.
- Published in:
- Diabetes, 1996, v. 45, n. 5, p. 695, doi. 10.2337/diab.45.5.695
- By:
- Publication type:
- Article
Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM.
- Published in:
- 1994
- By:
- Publication type:
- journal article
Isolation of the human LIM/homeodomain gene islet-1 and identification of a simple sequence repeat polymorphism [corrected].
- Published in:
- 1994
- By:
- Publication type:
- journal article
Hypoglycemia-induced autonomic failure in IDDM is specific for stimulus of hypoglycemia and is not attributable to prior autonomic activation.
- Published in:
- 1994
- By:
- Publication type:
- journal article
Recruitment strategies and yields for the Pathobiology of Prediabetes in a Biracial Cohort: a prospective natural history study of incident dysglycemia.
- Published in:
- BMC Medical Research Methodology, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2288-13-64
- By:
- Publication type:
- Article
Recruitment strategies and yields for the Pathobiology of Prediabetes in a Biracial Cohort: a prospective natural history study of incident dysglycemia.
- Published in:
- 2013
- By:
- Publication type:
- journal article
796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-796-P
- By:
- Publication type:
- Article
791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-791-P
- By:
- Publication type:
- Article
786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-786-P
- By:
- Publication type:
- Article
785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-785-P
- By:
- Publication type:
- Article
783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-783-P
- By:
- Publication type:
- Article
197-LB: microRNA Expression Profiles and Progression from Normoglycemia to Prediabetes in a Biracial Cohort.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-197-LB
- By:
- Publication type:
- Article
Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program.
- Published in:
- 2019
- By:
- Publication type:
- journal article
1719-P: Plasma Glucose Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Offspring of Parents with Type 2 Diabetes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1719-P
- By:
- Publication type:
- Article
1560-P: A History of CHF Predicts Adverse Outcomes of Hospitalizations for Hyperglycemic Crises—Data from National and Local Cohorts.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1560-P
- By:
- Publication type:
- Article
1507-P: Baseline Metabolite Profiles of Incident Type 2 Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program (DPP).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1507-P
- By:
- Publication type:
- Article
130-OR: Does the Duration of Prediabetes Status Affect Reversibility with Lifestyle Intervention?
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-130-OR
- By:
- Publication type:
- Article
1210-P: Pooled Analysis of the Safety and Efficacy of Ertugliflozin in the Elderly.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1210-P
- By:
- Publication type:
- Article
2426-PUB: Circulating WBC, RBC, and Hemoglobin Level in Relation to Metabolic Syndrome and Incident Prediabetes in a Biracial Cohort of Normoglycemic Subjects with Parental Type 2 Diabetes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-2426-PUB
- By:
- Publication type:
- Article
Comment on: Maruthur et al. Does genetic ancestry explain higher values of glycated hemoglobin in African Americans? Diabetes 2011;60:2434-2438.
- Published in:
- 2012
- By:
- Publication type:
- letter
Comment on: Maruthur et al. Does Genetic Ancestry Explain Higher Values of Glycated Hemoglobin in African Americans? Diabetes 2011;60:2434--2438.
- Published in:
- 2012
- By:
- Publication type:
- Opinion
Pathobiology of Prediabetes: Design and Methods for a Study of Early Dysglycemia in a Biracial Cohort.
- Published in:
- Diabetes, 2007, v. 56, p. A625
- By:
- Publication type:
- Article
Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence...[including commentary by Byron C. Scott].
- Published in:
- American Health & Drug Benefits, 2021, v. 14, n. 3, p. 101
- By:
- Publication type:
- Article
Effects of Medicare Part D on Disparity Implications of Medication Therapy Management Eligibility Criteria.
- Published in:
- American Health & Drug Benefits, 2014, v. 7, n. 6, p. 346
- By:
- Publication type:
- Article
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials.
- Published in:
- Clinical Cardiology, 2021, v. 44, n. 8, p. 1139, doi. 10.1002/clc.23665
- By:
- Publication type:
- Article
Leptin Response to Glucocorticoid Occurs at Physiological Doses and Is Abolished by Fasting.
- Published in:
- Obesity (19307381), 2003, v. 11, n. 2, p. 232, doi. 10.1038/oby.2003.36
- By:
- Publication type:
- Article
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.
- Published in:
- American Journal of Nephrology, 2022, v. 53, n. 7, p. 516, doi. 10.1159/000524889
- By:
- Publication type:
- Article
Calorie Restriction and Intermittent Fasting: Impact on Glycemic Control in People With Diabetes.
- Published in:
- Diabetes Spectrum, 2020, v. 33, n. 2, p. 143, doi. 10.2337/ds19-0064
- By:
- Publication type:
- Article
Management of Diabetes Mellitus in Surgical Patients.
- Published in:
- 2002
- By:
- Publication type:
- Journal Article
FROM RESEARCH TO PRACTICE. [Commentary on] Glycemic Control and Neuropsychologic Function During Hypoglycemia in Patients With Insulin-Dependent Diabetes Mellitus.
- Published in:
- 1994
- By:
- Publication type:
- Journal Article
FROM RESEARCH TO PRACTICE. [Commentary on] Glycemic Control and Neuropsychologic Function During Hypoglycemia in Patients With Insulin-Dependent Diabetes Mellitus.
- Published in:
- Diabetes Spectrum, 1994, v. 7, n. 4, p. 256
- By:
- Publication type:
- Article
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639
- By:
- Publication type:
- Article
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 8, p. 2042, doi. 10.1210/clinem/dgac764
- By:
- Publication type:
- Article
Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups.
- Published in:
- Journal of the American Geriatrics Society, 2019, v. 67, n. 3, p. 581, doi. 10.1111/jgs.15754
- By:
- Publication type:
- Article
Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose.
- Published in:
- 2009
- By:
- Publication type:
- journal article